Juno Therapeutics, Opus Bio deal

Juno will receive rights to an undisclosed CD22-targeted chimeric antigen

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE